Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?
Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.
We cover the latest cancer research, including that funded by the charity. We also highlight other relevant material, debunk myths and media scares, and provide links to other helpful resources.
Text from Cancer Research UK's News site by Cancer Research UK, is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License.